Population Pharmacokinetics of Imatinib in Nigerians With Chronic Myeloid Leukemia: Clinical Implications for Dosing and Resistance

• Published in: Journal of clinical pharmacology Vol. 57; no. 12; p. 1554
• Main Authors: Adeagbo, Babatunde Ayodeji, Olugbade, Tiwalade Adewale, Durosinmi, Muheez Alani, Bolarinwa, Rahman Ayodele, Ogungbenro, Kayode, Bolaji, Oluseye Oladotun
• Format: Journal Article
• Language: English
• Published: England 01.12.2017
• Subjects: Adolescent; Adult; African Continental Ancestry Group; Antineoplastic Agents - pharmacokinetics; Antineoplastic Agents - therapeutic use; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate - pharmacokinetics; Imatinib Mesylate - therapeutic use; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - epidemiology; Male; Middle Aged; Models, Biological; Nigeria - epidemiology; Reproducibility of Results; Young Adult; chronic myeloid leukemia; imatinib; genetic polymorphism; ABCB1 C3435T; CYP3A53; population pharmacokinetics
• ISSN: 1552-4604
• DOI: 10.1002/jcph.953

Imatinib, a tyrosine kinase inhibitor, is the drug of choice for the treatment of chronic myeloid leukemia in Nigeria. Several studies have established interindividual and interpopulation variations in imatinib disposition although no pharmacokinetic study have been conducted in an African population since the introduction of the drug. This study explored a population pharmacokinetic approach to investigate the disposition of imatinib in Nigerians and examined the involvement of some covariates including genetic factors in the variability of the drug disposition with a view to optimize the use of the drug in this population. A total of 250 plasma concentrations from 126 chronic myeloid leukemia patients were quantified using a validated method. A population pharmacokinetic model was fitted to the data using NONMEM VII software, and the influences of 12 covariates were investigated. The mean population-derived apparent steady-state clearance, elimination half-life, area under the concentration-time curve over 24 hours, and volume of distribution were 17.2 ± 1.8 L/h., 12.05 ± 2.1 hours, 23.26 ± 0.6 μg·h/mL, and 299 ± 20.4 L, respectively. Whole blood count, ethnicity, CYP3A5*3, and ABCB1 C3435T were found to have significant influence on the apparent clearance, while the interindividual variability in clearance and interoccasion variability in bioavailability were 17.4% and 20.4%, respectively. There was a wide variability in apparent clearance and area under the curve compared to those reported in other populations. Thus, treatment with a standard dose of imatinib in this population may not produce the desired effect in most of the patients, whereas continuous exposure to a low drug concentration could lead to pharmacokinetic-derived resistance. The authors suggest the need for therapeutic drug monitoring-guided dose individualization in this population.